Video - Results from #50

ASCO GU 2023 VL

Phase 3 ARASENS Study, The Impact of Disease Burden and Risk on Efficacy and Safety Outcomes - Matthew Smith Details Matthew Smith joins Alicia Morgans to discuss the post hoc analysis of the ARASENS study reporting the impact of disease burden and risk on efficacy and safety outcomes. The positive findings from the ARASENS study showed a significant improvement in overall survival, and those results supported the regulatory approval of darolutamide as part of triplet therapy in men with metastatic hormone-sensi...
The Role of Neoadjuvant Chemotherapy on Pathological Stage and Survival in Sarcomatoid Bladder Cancer – Arya Roy Details Arya Roy joins Alicia Morgans to discuss her work on the role of neoadjuvant chemotherapy on the sarcomatoid variant of bladder cancer. This research earned Dr. Roy a 2023 ASCO GU Merit Award at this year's ASCO Genitourinary Cancers Symposium. Sarcomatoid bladder cancer is an extremely rare and aggressive histological variant with a poor prognosis and limited consensus regarding its management. D...
Reduction in the Risk of Recurrence with the Use of Blue Light Cystoscopy Use Among Patients with Non-Muscle Invasive Bladder Cancer In An Equal Access Setting - Stephen Williams Details Sam Chang is joined by Stephen Williams to discuss the impact of Blue Light Cystoscopy (BLC) use among patients with non-muscle invasive bladder cancer (NMIBC) in an equal access setting, specifically the Veterans Affairs (VA) system. Prior studies suggest that white light cystoscopy (WLC) alone can fail to detect cases of NMIBC compared to BLC. Dr. Williams explains that they found a roughly 30%...
Treating Biochemical Recurrence With Enhanced Therapy Added to Standard of Care and Targeted Radiation Using PET Imaging, ECOG-ACRIN EA8191 (INDICATE) - Neha Vapiwala Details In this conversation, Neha Vapiwala joins Alicia Morgans in a conversation on the ECOG-ACRIN EA8191 (INDICATE) phase III trial in progress. In patients with prostate cancer who experience biochemical recurrence, the ECOG-ACRIN EA8191 (INDICATE) trial examines whether patients without PET-detected lesions outside the pelvis benefit from the addition of apalutamide to standard salvage radiotherapy +...
Results from the Phase 3 Study of 89Zr-DFO-Girentuximab for PET/CT Imaging of Clear Cell Renal Cell Carcinoma (ZIRCON) - Brian Shuch Details Brian Shuch joins Pedro Barata to discuss the recent results from ZIRCON, a phase 3 study of 89 Zr-DFO-girentuximab for PET/CT imaging of clear cell renal cell carcinoma (ccRCC). There is an unmet need for an accurate noninvasive method for pre-treatment risk stratification in detecting renal masses. The trial evaluated the efficacy of the imaging agent desferrioxamine-zirconium-girentuximab (Teli...
TROPHY-U-01 Cohort 3 Primary Analysis Sacituzumab Govitecan in Combination with Pembrolizumab in Patients with Metastatic Urothelial Cancer That Progressed after Platinum-Based Therapy - Petros Grivas Details Petros Grivas joins Alicia Morgans in a discussion on updated results of the phase II TROPHY-U-01 data from cohort 3, looking at the combination of pembrolizumab, anti-PD-1, plus sacituzumab govitecan, an antibody-drug conjugate against Trop-2 evaluated in 41 patients who had early progression resistance to platinum-based chemotherapy as a second-line therapy. Biographies: Petros Grivas, MD, Ph.D....
The Future of Immune Checkpoint Inhibitors in the First-Line Treatment of Metastatic Urothelial Carcinoma - Andrea Apolo Details Andrea Apolo, head of the bladder cancer section of the genitourinary malignancy branch within the NCI, joins Sam Chang to discuss first-line therapies for patients with advanced and metastatic urothelial carcinoma. Dr. Apolo explains that several clinical trials have been developed to improve outcomes in patients in the first-line setting by combining chemotherapy with checkpoint inhibitors. One...
HCRN GU 16-260, Nivolumab and Salvage Nivolumab+Ipilimumab in Patients with Advanced Renal Cell Carcinoma Cohort A, Treatment-Free Survival Outcomes - Michael Atkins Details Michael Atkins joins Pedro Barata in a conversation on Cohort A of a phase II study looking at treatment-free survival (TFS) outcomes of nivolumab and salvage nivolumab + ipilimumab in advanced clear cell renal cell carcinoma (HCRN GU16-260). This study was designed to potentially reduce the toxicity by sparing people ipi who didn't need it and also capping therapy in patients who were having a lo...
Cell-Free Urinary DNA Predictive Impact on Patients with Non-Muscle Invasive Bladder Cancer - Kyle Rose Details Kyle Rose joins Sam Chang in discussing his team's findings regarding the impact of cell-free urinary DNA on non-muscle invasive bladder cancer patients. This study aims to detect tumor alterations or mutations in the urine of high-risk non-invasive bladder cancer patients undergoing a repeat TURBT. Using whole exome sequencing and an ultra-deep sequencing platform, the study found that urinary tu...

ASCO GU 2023 VL

Login